vTv Therapeutics Inc. (VTVT) |
24 0.13 (0.54%) 04-18 11:08 |
Open: | 24 |
High: | 24 |
Low: | 24 |
Volume: | 610 |
Market Cap: | 58(M) |
PE Ratio: | -2.47 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 36.20 |
Resistance 1: | 30.99 |
Pivot price: | 24.83 |
Support 1: | 21.73 |
Support 2: | 16.01 |
52w High: | 39.6 |
52w Low: | 7.38 |
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
EPS | -9.710 |
Book Value | -11.840 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | -72.0 |
Return on Equity (ttm) | 0.0 |
Tue, 16 Apr 2024
Has vTv Therapeutics (VTVT) Outpaced Other Medical Stocks This Year? - Yahoo Movies UK
Wed, 13 Mar 2024
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewswire
Wed, 13 Mar 2024
VTv Therapeutics: Q4 Earnings Snapshot - Houston Chronicle
Mon, 04 Mar 2024
vTv Therapeutics starts phase 3 trial for diabetes drug - Investing.com
Fri, 01 Mar 2024
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference - Yahoo Finance
Thu, 29 Feb 2024
Should You Sell vTv Therapeutics Inc (VTVT) Stock Thursday Morning? - InvestorsObserver
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |